ELAN AND EISAI CONCLUDE AGREEMENT FOR THE DEVELOPMENT AND MARKETING OF NEW CERVICAL DYSTONIA AGENT FOR JAPAN
(October 10, 2000) - Elan Corporation, plc. of Ireland, (Chairman & CEO: Donal J. Geaney) and Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced the conclusion of an exclusive agreement for the development and marketing in Japan of Elan's new cervical dystonia agent (generic name: botulinum toxin type B) on September 29th.
Cervical dystonia is a condition of abnormal muscle tone and movement that can result in painful abnormalities of posture or inability to flex and relax affected neck and shoulder muscles. The botulinum toxin type B compound is effective in the treatment of cervical dystonia by relaxing affected neck and shoulder muscles through blocking the neurotransmitter acetylcholine in those patients responsive to butulinum toxin therapy treatment.
In Phase III clinical trial results in the U.S. and Europe, the compound demonstrated efficacy in the treatment of cervical dystonia compared to those patients who received a placebo. In addition, botulinum toxin type B was effective for those who no longer responded to currently available botulinum toxin type A products for cervical dystonia. The compound is currently under review by regulatory authorities in the U.S. and Europe.
< For additional inquiries contact: >